key: cord-0834908-jdd1bl7e
authors: Fernández‐Ruiz, Mario; López‐Medrano, Francisco; Pérez‐Jacoiste Asín, María Asunción; Maestro de la Calle, Guillermo; Bueno, Héctor; Caro‐Teller, José Manuel; Catalán, Mercedes; de la Calle, Cristina; García‐García, Rocío; Gómez, Carlos; Laguna‐Goya, Rocío; Lizasoáin, Manuel; Martínez‐López, Joaquín; Origüen, Julia; Pablos, José Luis; Ripoll, Mar; San Juan, Rafael; Trujillo, Hernando; Lumbreras, Carlos; Aguado, José María
title: Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: A single‐center cohort study
date: 2020-07-27
journal: J Med Virol
DOI: 10.1002/jmv.26308
sha: 1c849368b4341191d50b744d940d227d453eeab0
doc_id: 834908
cord_uid: jdd1bl7e

Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been proposed in this hyperinflammatory phase, although supporting evidence is limited. We retrospectively analyzed 88 consecutive patients with COVID‐19 pneumonia that received at least one dose of intravenous TCZ in our institution between 16 and 27 March 2020. Clinical status from day 0 (first TCZ dose) through day 14 was assessed by a 6‐point ordinal scale. The primary outcome was clinical improvement (hospital discharge and/or a decrease of ≥2 points on the 6‐point scale) by day 7. Secondary outcomes included clinical improvement by day 14 and dynamics of vital signs and laboratory values. Rates of clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88). Previous or concomitant receipt of subcutaneous interferon‐β (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06‐0.94; P = .041) and serum lactate dehydrogenase more than 450 U/L at day 0 (aOR: 0.25; 95% CI: 0.06‐0.99; P = .048) were negatively associated with clinical improvement by day 7. All‐cause mortality was 6.8% (6/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation/FiO(2) ratio increased by days 3 and 5, whereas C‐reactive protein levels dropped by day 2. There were no TCZ‐attributable adverse events. In this observational single‐center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID‐19 pneumonia.

of clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/ 88). Previous or concomitant receipt of subcutaneous interferon-β (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06-0.94; P = .041) and serum lactate dehydrogenase more than 450 U/L at day 0 (aOR: 0.25; 95% CI: 0.06-0.99; P = .048) were negatively associated with clinical improvement by day 7. All-cause mortality was 6.8% (6/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation/FiO 2 ratio increased by days 3 and 5, whereas C-reactive protein levels dropped by day 2. There were no TCZ-attributable adverse events. In this observational single-center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID-19 pneumonia. to reach pandemic proportions. 1 Although most cases have a mild to moderate disease course, a significant proportion of patients require hospital admission due to the development of pneumonia, which may ultimately result in acute respiratory distress syndrome (ARDS). 2 The case fatality rate among critically ill COVID-19 patients has been reported to exceed 50%. 3, 4 Beyond the direct viral cytopathic effect, the pathogenesis of severe SARS-CoV-2 infection involves a hyperinflammatory state that resembles the cytokine release syndrome (CRS) observed in patients with immune-mediated conditions or receiving chimeric antigen receptor (CAR) T-cell therapy. 5 The use of immunomodulatory therapies (such as corticosteroids, Janus kinase inhibitors, or colchicine) has been accordingly proposed to abrogate this deleterious hyperinflammatory response, although available clinical experience is limited.

The humanized anti-interleukin (IL)-6 receptor monoclonal antibody tocilizumab (TCZ) is being used off-label in patients with severe COVID-19 on the basis of the previous experience with CAR T-cell therapy-induced CRS and known safety profile. [6] [7] [8] However, until the results of ongoing clinical trials become available, supporting evidence was initially restricted to case reports [9] [10] [11] and a small study with only 21 patients from China. 12 Whether the blockade of IL-6 signaling at earlier stages of infection may modify the course of COVID-19 and reduce the requirements for invasive respiratory support remains to be addressed. We described our experience with patients consecutively diagnosed with COVID-19 pneumonia treated with TCZ and analyzed baseline predictors of therapeutic response to this immunomodulatory approach.

The present retrospective cohort study was performed at the University Hospital "12 de Octubre", a 1300-bed tertiary care center that serves a population of approximately 450 000 inhabitants in of the Hospital Universitario "12 de Octubre") approved the study protocol (CEIm no. 20/117) and granted a waiver of informed consent due to its observational design. The research was performed in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.

For analysis purposes, the date of administration of the first TCZ infusion was considered as day 0. Patients were followed up to hospital discharge or death (whichever occurred earlier), or 15 April 2020. Demographics and major comorbidities; clinical presentation; serial assessment of vital signs, respiratory status, laboratory values, and radiological features; antiviral and other immunomodulatory therapies; attributable adverse events; and outcomes were collected from electronic medical records using a standardized case report form. All laboratory and imaging investigations were performed as part of standard of care. Respiratory function was assessed by means of the pulse oximetry oxygen saturation/fraction of inspired oxygen (SpO 2 /FiO 2 ) ratio, which shows a good correlation with the partial pressure of arterial oxygen (PaO 2 )/FiO 2 ratio. 13 Variations (Δ) in vital signs and laboratory values between days 0 and 3 were calculated ([X day 3 − X day 0 ] × 100/X day 0 ). To this end, the latest measurement available throughout this 3-day period was used.

A 6-point ordinal scale was applied to analyze clinical status on the basis of the following categories: 1 = not hospitalized; 2 = hospitalized, not requiring supplemental oxygen; 3 = hospitalized, requiring low-flow supplemental oxygen (FiO 2 <40%); 4 = hospitalized, requiring high-flow supplemental oxygen (FiO 2 ≥40%) or noninvasive mechanical ventilation; 5 = hospitalized, requiring invasive mechanical ventilation (IMV), extracorporeal membrane oxygenation (ECMO), or both; and 6 = death.

The primary study outcome was the proportion of patients achieving Due to initial uncertainties on TCZ effectiveness and safety and potential drug shortages, a multidisciplinary committee that included all the clinical specialties involved and the Department of Pharmacy was established to standardize therapeutic decisions. The off-label use of TCZ was considered in patients potentially eligible for IMV, with bilateral (or rapidly progressive) interstitial or alveolar infiltrates in chest X-ray or computerized tomography (CT) scan, and fulfilling at least one of the following criteria: (a) respiratory frequency more than 30 breaths per minute and/or SpO 2 less than 92% on room air; (b) CRP levels more than 10 mg/dL; (c) IL-6 levels more than 40 pg/mL; and/or (d) D-dimer level more than 1500 ng/mL. Exclusion criteria included the presence of alanine aminotransferase and/or aspartate aminotransferase levels more than five times the upper normal limit, uncontrolled systemic infection due to other pathogens, or complicated acute diverticulitis or bowel perforation.

An initial IV 400 mg (if body weight <75 kg) or 600 mg (if body weight ≥75 kg) TCZ dose was administered as 1-hour infusion. A second 400 mg dose was administered 12 hours later, whereas a third dose could be given after 24 hours from the first infusion to selected patients that had achieved only a partial response.

The diagnosis of COVID-19 was made by means of SARS-CoV-2 realtime reverse transcription-polymerase chain reaction in nasopharyngeal or oropharyngeal swabs or sputum samples, as detailed in Supporting Information Methods. The diagnosis was also assumed in patients with a suggestive clinical and radiological presentation and compatible epidemiological history but repeatedly negative testing.

Quantitative data were shown as the mean ± standard deviation or the median with interquartile range (IQR), whereas qualitative variables were expressed as absolute and relative frequencies.

Categorical variables were compared using the χ 2 test. The Student t test or the Mann-Whitney U test were applied for continuous variables, as appropriate. Repeated measurements were compared using paired parametric or nonparametric tests (the Student t test for paired samples, the Wilcoxon signed-rank test or Friedman test), as dictated by data distribution. Baseline factors predicting clinical improvement at days 7 and 14 were analyzed by logistic regression, with associations expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs). The potential effect of unintended variations in patient selection across the study period was assessed according to the calendar date of the first TCZ dose (16 to 20 March 

We included 88 patients whose demographics and clinical characteristics are shown in Table 1 Figure S1 in Supporting Information. All-cause mortality was 6.8% (6/88), with a median interval from day 0 to death of 6 (IQR: 3-11.5) days. were younger, less likely to be male, exhibited longer duration of symptoms, and had higher SpO 2 /FiO 2 ratio and lower LDH and IL-6 levels at baseline as compared with those with no improvement. In addition, they were less likely to have been treated with IFN-β and more likely to have received azithromycin (Table S1 ). Due to the low number of patients not experiencing improvement by day 14, multivariate analysis could not be performed.

The serial assessment of vital signs revealed that axillary temperature and respiratory and cardiac rates significantly decreased with respect to baseline already by day 1, whereas the SpO 2 /FiO 2 ratio showed a significant increase only by day 5 (Figure 2 ). Regarding laboratory parameters, absolute lymphocyte counts significantly increased by day 3, whereas CPR levels dropped by day 2.

D-dimers increased through days 2 and 3, although this parameter was available for a low number of patients ( Figure 3 ). (Table S2) . 

As highlighted by the Infectious Disease Society of America, 15 PaO 2 /FiO 2 ratio. 19 A small retrospective case-control study reported that the use of TCZ was associated with lower mortality and/or admission rate to the intensive care unit (ICU), despite the higher comorbidity burden and more severe COVID-19 forms exhibited by these patients as compared to the control group. 20 No attributable adverse events were reported in none of these studies, 10, 12, 19, 20 were still in the ICU and 12% had dead. 28 On the contrary, the administration of TCZ within the first 6 days from hospital admission was associated with an increased likelihood of survival in a further study. 19 In a recent retrospective study performed in three Italian centers, Guaraldi et al 29 reported that the use of TCZ (either IV or SC) reduced the risk of IMV or death as compared to standard care alone. 29 It should be noted that the patients included in that study were substantially older than ours (median age of 61 vs 45.5 years, respectively) and had higher The present study has a number of limitations, the most relevant of which is the lack of a control group. Indeed, we cannot exclude that the overall favorable results observed for TCZ- 

Cristina García Sánchez; Department of Medical Oncology: Carmen Díaz-Pedroche, Flora López, Luis Paz-Ares; Department of Intensive Care Medicine: Jesús Abelardo Barea Mendoza

Department of Emergency Medicine

5 Impact of patient status according to the 6-point ordinal scale at day 0 on the clinical outcome by day 7 after the administration of the first tocilizumab dose. ECMO, extracorporeal membrane oxygenation

IMV, invasive mechanical ventilation REFERENCES

A novel coronavirus from patients with pneumonia in China

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Covid-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine

Off-label use of tocilizumab in patients with SARS-CoV-2 infection

Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab

Effective treatment of severe COVID-19 patients with tocilizumab

Comparison of the SpO 2 / FIO 2 ratio and the PaO 2 /FIO 2 ratio in patients with acute lung injury or ARDS

Documento técnico de manejo clínico de pacientes con enfermedad por el nuevo coronavirus (COVID-19) (versión 3 de Marzo de 2020)

Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (Version 1.0.4)

Compassionate use of remdesivir for patients with severe Covid-19

High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients

IL-6: regulator of Treg/Th17 balance

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv

Tocilizumab treatment in COVID-19: a single center experience

Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation

Elevated lactate dehydrogenase values in patients with Pneumocystis carinii pneumonia

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome

Impaired immune and acute-phase responses in interleukin-6-deficient mice

Tocilizumab for the treatment of severe coronavirus disease 2019

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Lack of dyspnea in Covid-19 patients; another neurological conundrum?

Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study

The authors would like to acknowledge all the healthcare workers involved in the response to the current pandemic in our institution and, particularly, those affected by COVID-19. This work was supported by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181)-cofinanced by European Development Regional Fund "A way to achieve Europe." Rocío García-García http://orcid.org/0000-0003-4265-8567

Joaquín Martínez-López http://orcid.org/0000-0001-7908-0063Hernando Trujillo http://orcid.org/0000-0002-3520-1422José María Aguado http://orcid.org/0000-0002-9520-8255